From Name:
From Email:
To Name:
To Email:

Optional Message:


ASCO recommends EGFR testing for NSCLC, but for which patients?

from Medscape

Epidermal growth-factor receptor (EGFR) mutation testing is now recommended by the American Society of Clinical Oncology (ASCO) for patients with advanced nonsmall-cell lung cancer (NSCLC) who are "considering" first-line therapy with the EGFR tyrosine kinase inhibitors (TKIs) erlotinib (Tarceva) and gefitinib (Iressa). more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063